+ All Categories
Home > Documents > Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees...

Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees...

Date post: 28-May-2020
Category:
Upload: others
View: 6 times
Download: 0 times
Share this document with a friend
20
1 Evonik Venture Capital October 2016
Transcript
Page 1: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

1

Evonik Venture Capital

October 2016

Page 2: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

2

Table of contents

1. Evonik at a glance

2. Evonik Venture Capital

3. Specialty Chemical segments

| October 2016 | Evonik Venture Capital

Page 3: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

3

Employees December 31, 2015

33,57618.2 %Profitability (adjusted EBITDA margin)

€2.465 billion Adjusted

EBITDAReturn on capital

Employed (ROCE)

16.6 %

€13.5 billionsales

2015: Evonik in figures

| October 2016 | Evonik Venture Capital

Page 4: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

4

Leading in Specialty Chemicals

Leading market

positions in

80% of our businesses1

Strong customer intimacy

and tailor-made solutions

with

almost 90% of direct sales

Most products with

small volume

but big impact in customers’ end

products

~500

R&D projects driving future sales

potential

Average

volume growthfrom 2010 until 2015

more than 4% in our growth segments2

Market leader Customer proximity Value proposition Innovation power Growth profile

| October 2016 | Evonik Venture Capital

1. Sales with top 1-3 market position by sales, production volume or capacity (depending on available data) | 2. Nutrition & Care and Resource Efficiency

Page 5: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

5

Consistent execution of differentiated segment strategy

| October 2016 | Evonik Venture Capital

Nutrition

& Care

Resource

Efficiency

Performance

Materials

Growth Efficiency

€4,924 m €1,435 m / 29.1% €4,279 m €896 m / 20.9%

Sales

€3,435 m

Adj. EBITDA / Margin

€309 m / 9.0%

Sales Adj. EBITDA / MarginSales Adj. EBITDA / Margin

Sales

€13,507 m

Adj. EBITDA

€2,465 m

Margin

18.2%

ROCE

16.6%

2015 Financials

Page 6: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

6

Evonik Group22 Business Lines grouped in 3 segments

Animal Nutrition

Baby Care

Health Care

Personal Care

Household Care

Comfort & Insulation

Interface & Performance

Silica

Crosslinkers

Oil Additives

Coating & Adhesive Resins

High Performance Polymers

Active Oxygens

Silanes

Coating Additives

Catalysts

Performance Intermediates

Methacrylates

Acrylic Products

Functional Solutions

Agrochemicals & Polymer Additives

CyPlus Technologies

| October 2016 | Evonik Venture Capital

2015 financials; Business Lines ranked by turnover

Nutrition

& Care

Resource

Efficiency

Performance

Materials

€4,924 m €1,435 m / 29.1% €4,279 m €896 m / 20.9%

Sales

€3,435 m

Adj. EBITDA / Margin

€309 m / 9.0%

Sales Adj. EBITDA / MarginSales Adj. EBITDA / Margin

Page 7: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

7

Growth strategy based on three strong pillars

Investments Innovation M&A

Sharpening of specialty chemicals portfolio

Additional route for growth and value creation

world-scale production plants erected and

currently in ramp-up1

7Acquisition of the Specialty & Coating

Additives business of Air Products

~ 3.8 bn USD

Expansion of global production footprint

Strengthen leading market positions worldwide

Market- and customer-oriented R&D approach

Product and process innovation

R&D employees drive our innovation

efforts across the group

~ 2,700

| October 2016 | Evonik Venture Capital

1. Construction between 2012 and 2015

Page 8: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

8

Innovation excellence: Evonik growth fieldsLeveraging our core competencies into highly attractive markets

| October 2016 | Evonik Venture Capital

Evonik Growth Fields

Healthcare Solutions

Smart Materials

Sustainable Nutrition

Cosmetic Solutions Membranes

Advanced Food Ingredients

Evonik Technology Competence Fields

Polymer DesignInorganic

Particle Design

Interfacial

Technologies

Coating & Bonding

Technologies

Catalytic

ProcessesBiotechnology

Additional

contribution

to sales

Megatrends

Health & Nutrition GlobalizationResource Efficiency

more

than

€1 billion

by 2025

Page 9: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

9

Table of contents

1. Evonik at a glance

2. Evonik Venture Capital

3. Specialty Chemical segments

| October 2016 | Evonik Venture Capital

Page 10: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

10

Evonik Venture Capital strategic investor advantage

As a strategic investor we actively collaborate with our portfolio companies

We leverage the strengths of Evonik to drive growth at portfolio companies through

strategic, technical and commercial expertise:

Cooperation with Evonik can provide:

technological expertise and infrastructure

know-how of manufacturing processes and production scale-up

market experience and global access

expertise in patent strategies and on issues of intellectual property rights

reputation and financial strength

| October 2016 | Evonik Venture Capital

Page 11: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

11

Evonik Venture Capital investment focus

Lubricant additives (viscosity modifiers)

Fuel additives

Additives for eco-friendly and highly solid

industrial coatings

Crosslinkers for composites, elastomers

and non-solvent coatings

Functional resins

Adhesive hot melts

Heat sealants

Precipitated and fumed silica

High perf. polyamide (PA12)

Polyetheretherketone (PEEK)

Membranes and polyimide fibres

Activated base metal catalysts

Catalysts for industrial & petrochemicals

Plastics

Styrene-butadiene-rubber

High performance polymers

LED/touch screens

Construction

Light-weight systems

Automotive components

Polymer additives

Optical brighteners

Agro chemicals

Methylmethacrylate (MMA) & application

monomers

Methacrylic acid

Feed additives and services for animal

nutrition

Active pharma ingredients

Drug delivery systems for oral and

parenteral dosage

Tailor-made pharmaceutical syntheses

Pharma amino acids

Actives, emulsifiers and conditioners for

personal care applications

Superabsorbents for baby care, female

care and adult care

Foam stabilizers, catalysts and release

agents

Specialty surfactants

Release coatings and super spreading

additives for packaging, agrochemicals

and plastic additives

Nutrition & Care Resource Effficency Performance Materials

| October 2016 | Evonik Venture Capital

Page 12: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

12

Evonik Venture Capital investment outline

We make medium-term investments in start-up companies and venture capital funds

throughout the world, with a total volume of up to €100 million.

We generally maintain a minority share and typically invest up to €5 million per

company.

investments are driven by financial returns and strategic goals

in innovative companies within key megatrends and new growth fields of Evonik

typically in series A & B rounds of companies that have already entered the market

or are about to do so

typically in syndication with other venture capital investors

| October 2016 | Evonik Venture Capital

Page 13: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

13

Evonik Venture Capital portfolio (I)

| October 2016 | Evonik Venture Capital

Page 14: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

14

Evonik Venture Capital portfolio (II)

Airborne Oil&Gas - www.airborne-oilandgas.com

Flexible composite pipes for the Oil & Gas industry.

Algal Scientific - www.algalscientific.com

Beta-glucan as nutritional supplement for feed- and food

applications.

Biosynthetic Technologies - www.biosynthetic.com

Bio-based synthetic oils for the lubricant and cosmetics

industries.

FRX Polymers - www.frxpolymers.com

Non-halogen, poly-phosphonates – fire-resistant plastics.

JenaCell - www.jenacell.com

Bio-based nanocellulose for wound care and cosmetics.

Nanocomp - www.nanocomp.fi

Micro- and nano-optical structures for electronic applications.

Synoste - www.synoste.com

Patient friendly solutions for correcting skeletal deformations.

Vivasure - www.vivasuremedical.com

Bio-absorbable closure device for large bore holes in the

femoral artery.

Wiivv Wearables - www.wiivv.com

3-D printed, biomechanically optimized insoles.

Emerald Technology Ventures - www.emerald-ventures.com

Focus on energy, water and materials in Europe and North

America.

GRC SinoGreen Fund - www.grcfunds.com

Focus on material focused green technology companies in

China.

High-Tech Gründerfonds - www.high-tech-gruenderfonds.de

Focus on German early stage companies.

Pangaea Ventures - www.pangaeaventures.com

Focus on advanced materials companies in North America.

| October 2016 | Evonik Venture Capital

Page 15: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

15

Evonik Venture Capital investment team

| October 2016 | Evonik Venture Capital

Main Office – Hanau, Germany

Bernhard Mohr

Managing Director

Monika Braun

Executive Assistant

Petra Riva

Executive Assistant

Mona Friedrich

Financial Analyst

Anette Kübler

Senior Venturing

Manager

Mark Redshaw

Investment Director

Jakob Wirbatz

Investment Director

Stephan Wolf

Investment Manager

Office – Essen, Germany

Jens Busse

Investment Manager

Office – Parsippany, NJ Office – Woodlands, TX

Lutz Stoeber

Investment Director

Eric Breese

Investment Manager

www.evonik.com/venturing

Page 16: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

16

Table of contents

1. Evonik at a glance

2. Evonik Venture Capital

3. Specialty Chemical segments

| October 2016 | Evonik Venture Capital

Page 17: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

17

Nutrition & CareBusiness Line overview

| October 2016 | Evonik Venture Capital

Animal Nutrition

• Methionine

• Lysine, Threonine,

Tryptophan

• Feed additives and

services for animal

nutrition

Personal Care

• Personal care

• Actives

• Emulsifiers

• Conditioners

Household Care

• Laundry care

• Home care

• Car care

• Fabric conditioners

• Specialty surfactants

Baby Care

• Baby care

• Female care

• Adult care

• Superabsorbers

Ke

y

pro

du

cts

Ma

in

Ap

pli

cati

on

s

Ke

y

pro

du

cts

Ma

in

Ap

pli

cati

on

s

Health Care

• Active pharma ingredients

• Pharma grade amino acids

• Pharmaceutical coatings

• Drug delivery systems for

oral and parenteral dosage

• Tailor-made

pharmaceutical synthesis

• Pharma amino acids

Comfort & Insulation

• Foam stabilizers

• Catalysts

• Release agents

• Furniture / applications

• Construction

• Automotive

Interface & Performance

• Release coatings

• Super spreading additives

• Packaging / tapes

• Agrochemicals

• Plastic additives

Page 18: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

18

Resource EfficiencyBusiness Line overview

| October 2016 | Evonik Venture Capital

Silica

• Precipitated silica

• Fumed silica

• Special oxides

• Silicone rubber

• Tires, green tires & rubber

• Paints & coatings

• Adhesives & sealants

Crosslinkers

• Composites

• Coatings & paints

• Flooring

• Automotive interior

• Crosslinkers for

composites, elastomers

and non-solvent coatings

Coating Additives

• Eco-friendly coatings (low

VOC, water based)

• High solid industrial

coatings

• Additives for eco-friendly

and highly solid industrial

coatings

Oil Additives

• Auto & industrials

• Hydraulic systems

• Refinery processing

• Biofuels

• Lubricant additives

(viscosity modifiers)

• Fuel additives

Ke

y

pro

du

cts

Ma

in

Ap

pli

cati

on

s

Ke

y

pro

du

cts

Ma

in

Ap

pli

cati

on

s

Active Oxygens

• Oxidising agent in

chemical reactions

• Pulp & paper bleaching

• Hydrogen peroxide

Catalysts

• Activated base material

catalysts

• Precious metal catalysts

• Catalysts for industrial &

petrochemicals

• Silicone rubber

• Tires, green tires & rubber

• Paints & coatings

• Adhesives & sealants

High Performance

Polymers

• High perf. polyamide

• Polyetheretherketone

• Membranes and Polyimide

fibres

• Automotive components

• Medical

• Oil & gas pipes

Coating & Adhesive

Resins

• Functional resins

• Adhesive hot melts

• Heat sealants

• Polybutadiene

• Hot melt

• Pre coated metal

• Protective coatings

• Road marking

Silanes

• Chlorsilanes

• Organofunctional silanes

• Rubber silanes

• Fumed silica

• Optical fibres

• Adhesive & sealants

• Building protection

Page 19: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

19

Performance MaterialsBusiness Line overview

| October 2016 | Evonik Venture Capital

Performance

Intermediates

• Butadiene

• MTBE

• Butene-1

• Plasticizers (INA&DINP)

• Plastics

• Styrene-Butadiene-Rubber

• High performance

polymers

Acrylic Polymers

• LED/touch screens

• Construction

• Light-weight systems

• Automotive components

• Molding compounds

• Acrylic sheets (Plexiglas /

Acrylite)

• PMMA systems

Acrylic Monomers

• Coatings

• PMMA

• Monomers for specialty

applications

• Methylmethacrylate

(MMA) & application

monomers

• Methacrylic acid

Ke

y

pro

du

cts

Ma

in

Ap

pli

cati

on

s

Ke

y

pro

du

cts

Ma

in

Ap

pli

cati

on

s

Agrochemicals

• Triacetonamine

• Crosslinkers

• Precursors of glyphosates

• Polymer additives

• Optical brighteners

• Photovoltaic

• Agro chemicals

Functional Solutions

• Alkoxides

(e.g. sodium methylate)

• Catalysts for biodiesel

production

CyPlus Technologies

• Sodium cyanide

• Potassium cyanide

• Precious metals mining

• Fine chemicals

Page 20: Evonik Venture Capitalncet2.org/images/2017ConferenceDemo/slides/05-Evonik.pdf · 3 Employees December 31, 2015 33,576 18.2 % Profitability (adjusted EBITDA margin) €2.465 billion

20


Recommended